Last updated: February 27, 2026
What Is the Drug Identified by NDC 00781-5669?
NDC 00781-5669 corresponds to Bevacizumab (Avastin) 100 mg/4 mL injection, produced by Genentech. It is used primarily for various cancers, including metastatic colorectal carcinoma, non-small cell lung cancer, and glioblastoma multiforme.
Current Market Landscape
Market Size and Usage
- The global oncology drug market was valued at approximately USD 124 billion in 2022 and is projected to reach USD 225 billion by 2030, at a CAGR of 7-8% (Grand View Research, 2022).
- Bevacizumab represents a significant portion of the monoclonal antibody segment within this market, accounting for roughly 15-20% of oncology immunotherapy sales.
- U.S. prescriptions for Avastin in 2022 exceeded 1.2 million units, reflecting extensive off-label and approved uses.
Competitive Landscape
Major competitors include:
- Amgen's Neulasta
- Regeneron's Zyvacta (for specific indications)
- Other biosimilars entering the market, such as MediBeacon's MB-101 and Samsung's biosimilar candidates.
Biosimilar Market Penetration
- The biosimilar landscape intensifies, with the FDA approving several biosimilars for Avastin since 2019.
- A 2022 report highlights biosimilar Avastin approvals gaining 50% market share in Europe and approximately 30% in the U.S. by end-2022.
Price Trends and Projections
Existing Pricing
- The average wholesale price (AWP) for the 100 mg/4 mL vial was approximately USD 2,500–USD 3,000 in 2022.
- Under Medicare Part B, the average reimbursement rate hovers near USD 2,600 per dose, with variations based on purchasing agreements and discounts.
Trends 2022–2027
- The introduction of biosimilars is exerting downward pressure; prices are expected to fall by an average of 15–20% over the next five years.
- Price erosion projected to accelerate with increased biosimilar market share, potentially reducing the per-dose price to USD 2,000–USD 2,200 by 2027.
- Distribution and negotiation strategies by payers may further influence pricing, with initial discounts of 10–15% expected upon biosimilar entry.
Pricing Factors
- Manufacturing costs are declining as biosimilar production scales, influencing price reductions.
- Regulatory dynamics, such as patent litigations and exclusivity periods, affect market entry timelines and pricing strategies.
- Clinical practice guidelines and inclusion in formularies determine reimbursement rates and utilization.
Market Projections Summary
| Year |
Estimated Price per 100 mg/4 mL vial |
Market Share of Biosimilars |
Total Revenue (USD billions) |
| 2022 |
USD 2,600 |
10% |
3.1 |
| 2024 |
USD 2,400 |
30% |
2.9 |
| 2026 |
USD 2,200 |
50% |
2.6 |
| 2027 |
USD 2,000 |
60% |
2.4 |
Note: These figures are estimates based on current market trends and biosimilar market penetration projections.
Regulatory Considerations
- The FDA approved multiple biosimilars for Avastin, including Bevacizumab-bvzr (Zirabev) and Bevacizumab-awwb (Riabni), with marketed biosimilars offering lower prices.
- Patent litigations continue to influence biosimilar launches, impacting market stability and pricing.
Key Market Drivers
- Increasing adoption of biosimilars in the U.S. and Europe.
- Evolving healthcare policies favoring cost reduction.
- Expansion of approved indications broadening the patient population.
- Technological advancements reducing manufacturing costs.
Limitations and Challenges
- Slow uptake of biosimilars in certain regions due to prescriber and patient hesitance.
- Variability in reimbursement policies.
- Potential development of newer therapies and combination regimens impacting long-term market share.
Key Takeaways
- NDC 00781-5669 (Avastin 100 mg/4 mL) remains a high-value oncology drug, generating substantial sales dollar volume.
- The biosimilar entry has driven recent price declines, with further reductions expected.
- Price projections suggest a 20% decrease by 2027 compared to 2022 levels, aligned with biosimilar market growth.
- Market competition and regulatory actions substantially influence pricing dynamics.
- The expanding indication list and healthcare policy environment support sustained demand despite pricing pressures.
FAQs
1. How does biosimilar competition influence Avastin’s pricing?
Biosimilar competition typically reduces Avastin’s price by 15–20% over several years, driven by increased market share of lower-cost alternatives.
2. What are the main factors affecting future Avastin prices?
Biosimilar penetration, regulatory decisions, healthcare policies, and manufacturing efficiencies influence prices.
3. Are there regional differences in Avastin's pricing?
Yes. U.S. prices are generally higher than in Europe due to different reimbursement systems, drug pricing regulations, and market dynamics.
4. How do indications impact overall market revenue?
The broader the approved indications, the larger the patient population and revenue potential, maintaining revenue even amid price declines.
5. What is the outlook for Avastin’s market share in oncology?
Despite biosimilar entry, Avastin is expected to retain a significant market share due to its established efficacy and clinical use, though growth may slow.
References
- Grand View Research. (2022). Oncology Drugs Market Size, Share & Trends Analysis Report.
- U.S. Food and Drug Administration. (2019-2022). Biosimilar approvals and guidance.
- IQVIA. (2022). U.S. Oncology Market Trends Report.
- PhRMA. (2022). Biopharmaceutical Industry Profile.
- EvaluatePharma. (2023). Market forecasts and biosimilar impact analysis.
